Product Description
VONJO is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a platelet count below 50 × 109/L. (Sourced from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5ab444-0e1a-4984-99db-76ad11a298ee)
Mechanisms of Action: JAK2 Inhibitor,IRAK1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Accelerated Approval - Myelofibrosis|Thrombocytopenia *
Approval Status: Approved
Approved Countries: United States
Approved Indications: None
Known Adverse Events: None
Company: CTI BioPharma
Company Location: SEATTLE WA 98121
Company CEO: Adam R. Craig
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belarus, Belgium, Bosnia, Bulgaria, Canada, Czech Republic, France, Georgia, Germany, Hungary, India, Israel, Italy, Kazakhstan, Korea, Netherlands, Poland, Romania, Russia, Serbia, Spain, Ukraine, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 12
Highest Development Phases
Phase 3: Myelofibrosis|Polycythemia Vera|Thrombocythemia, Essential|Thrombocytopenia|Thrombocytosis
Phase 2: Acute Monocytic Leukemia|Acute Myelomonocytic Leukemia|Chronic Myelomonocytic Leukemia|Juvenile Myelomonocytic Leukemia,|Myelodysplastic Syndrome
Phase 1: Healthy Volunteers|Hepatic Insufficiency
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PAC601 | P2 |
Unknown Status |
Unknown |
2027-08-26 |
|
| PAXIS | P2 |
Not yet recruiting |
Myelodysplastic Syndrome |
2027-08-01 |
|
| jRCT2031240668 | P3 |
Recruiting |
Myelofibrosis |
2027-07-31 |
|
| PAC303 | P3 |
Unknown Status |
Myelofibrosis |
2027-06-30 |